Back to search results

Functional Resistance Training for Older Cancer Survivors (The ACES Trial)

This study, called The ACES Trial, is looking at whether online group functional resistance training can help older cancer survivors (age 65 and up) who have difficulty with daily activities. You could join if you were diagnosed with cancer (stages I-IV) within the last 5 years and finished your main cancer treatments more than 3 months ago. The study will compare Functional Resistance Training to stretching and relaxation exercises, or to a delayed start of the resistance training. The main goal is to see if these programs are practical and if people will attend them. The study is currently recruiting 150 participants.

Study design
This is a randomized controlled trial with three groups, involving 150 participants. You would be randomly assigned to one of the three groups.
What's involved
You would attend live, online supervised group sessions three times a week for 45 minutes, for 16 weeks.
Compensation
Not stated in the trial record.
Follow-up
The study measures loss to follow-up, permanent discontinuation, and attendance at 16 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07606313

Phase I Randomized Controlled Trial of Functional Resistance Training in Older Cancer Survivors: The ACES Trial

Not Yet Recruiting
NAAges 65+InterventionalSupportive care
OHSU Knight Cancer Institute
~150 participants
Updated 2026-05-26 on ClinicalTrials.gov
What's tested:Functional Resistance TrainingStretchingDelayed Functional Resistance Training

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Loss-to-Follow Up
Measured over 16 weeks
+6 more outcomes measured

Conditions

Hematopoietic and Lymphatic System Neoplasm
Malignant Solid Neoplasm
Cancer
Functional Limitation

Explore related trials

Malignant Neoplasm

Where it's being run

1 sites across 1 states
Oregon1

Study leadership

  • Kerri Winters-Stone, Ph.D. · PRINCIPAL_INVESTIGATOR · OHSU Knight Cancer Institute

Who to contact

Kerri Winters-Stone, Ph.D.
[email protected]
503-494-0813
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age 65 years of age or older
Diagnosed with stage I-IV cancer =\< 5 years ago
Completed surgery, chemotherapy, or radiation therapy \> 3 months ago (concurrent maintenance therapy, such as hormone therapy for breast or prostate cancer, is permissible)
Self-report at least one limitation in Activities of Daily Living (ADLs) OR at clinical risk of developing ADL impairment as evidenced by a 3-meter timed-up-and-go time \> 13.5 seconds or 5-time chair stand time \> 12 seconds
Able to ambulate independently; reliance on assistive devices other than a wheelchair is allowed
Currently underactive (an average of \< 30 minutes of moderate-vigorous intensity exercise 3 days/week over the past four weeks)
Willing to be randomized into any of the three study arms and attend 80% or more of planned exercise sessions
Home internet sufficient for videoconferencing

Exclusion

Contraindication to moderate intensity exercise
Health or medical condition that affects movement or neurological disorder, or medication that contraindicates participation in live remote resistance exercise
Cognitive impairment consistent with moderate dementia (confirmed by a Montreal Cognitive Assessment (MoCA) score \< 14). Cognitive impairment consistent with early-stage dementia (a MoCA score of \<20) unless a research partner (e.g., family member, caregiver, close friend) can also be consented and can assist in answering the survey questions, participating in the performance tests, or giving informed consent.
Not fluent in English and therefore incapable of answering survey questions, following directions during exercise or performance testing, and providing informed consent in English

What this trial measures

  • Loss-to-Follow Up16 weeks

    Measured by the percentage of enrolled participants not completing baseline and 16-week survey or performance testing.

  • Permanent Discontinuation16 weeks

    Measured by the percentage of enrolled sample that the participant and/or the investigator withdraws before final study visit.

  • Attendance16 weeks

    Measured by the percentage of prescribed online sessions attended over the intervention period

  • Treatment Interruption16 weeks

    Measured by number of times 3+ consecutive sessions are missed over the 16 week intervention period

  • Dose Modification16 weeks

    Measured by the number of sessions requiring reduction or escalation in intensity and/or duration (sets or repetitions) after the session begins over the intervention period

  • Pre-treatment Dose Modification16 weeks

    Measured by the number of times a session dose (intensity and/or duration) is reduced or escalated prior to the beginning of a session over the intervention period

  • Tolerability (Relative Dose Intensity)16 weeks

    Measured by the cumulative dose of training received divided by the cumulative dose of prescribed training, expressed as a percentage over the intervention period